Bronchopulmonary Dysplasia Market: Expanding Revenue Landscape to 2034 - DelveInsight

DelveInsight's "Bronchopulmonary Dysplasia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bronchopulmonary Dysplasia, historical and forecasted epidemiology as well as the Bronchopulmonary Dysplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Bronchopulmonary Dysplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bronchopulmonary Dysplasia Market Forecast
https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Bronchopulmonary Dysplasia Market Report:
• The Bronchopulmonary Dysplasia market size was valued approximately USD 0.028 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In October 2024, Airway Therapeutics, Inc., a biopharmaceutical company focused on developing a new class of biologics to disrupt the cycle of injury and inflammation in respiratory and inflammatory diseases, announced it will initiate a multinational Phase 3 clinical trial in December 2024. The trial will evaluate zelpultide alfa (rhSP-D) for the prevention of bronchopulmonary dysplasia (BPD) and reduction of associated lung damage in preterm infants.
• In 2023, the total number of incident cases of Bronchopulmonary Dysplasia (BPD) in the 7MM was approximately 17,091. It is projected that these cases will rise by the year 2032.
• In 2023, the United States reported the highest number of incident cases of Bronchopulmonary Dysplasia (BPD) among the 7MM, totaling around 13,276 cases.
• In the EU4 countries and the UK, Germany reported the highest incidence of Bronchopulmonary Dysplasia (BPD) with 930 cases in 2023, followed closely by France with 920 cases. In contrast, Spain had the lowest incidence of BPD in the same year.
• According to DelveInsight's analysts, assessments indicate that in the United States, there were about 5,225 cases of Bronchopulmonary Dysplasia (BPD) among preterm infants weighing ≤750 g, followed by 5,043 cases in the 751-1000 g group, 2,300 cases in the 1001-1250 g group, and 709 cases in the ≥1250 g group in 2023.
• Currently, the Bronchopulmonary Dysplasia pipeline is sparse, featuring primarily OHB607 (mecasermin rinfabate), an intravenous infusion under development by Oak Hill. Additional developments include PNEUMOSTEM (Human Umbilical Cord Blood Derived Mesenchymal Stem Cells) by Medipost, and AT-100 by Airway Therapeutics, among others.
• Key Bronchopulmonary Dysplasia Companies: Chiesi Farmaceutici S.p.A., AyuVis Research, Airway Therapeutics, Inc, Meridigen Biotechnology, Medipost Co., Ltd., Oak Hill Bio Ltd., Mallinckrodt, The Emmes Company, LLC, Medipost Co Ltd, and others
• Key Bronchopulmonary Dysplasia Therapies: OHB-607, AVR-48, AT-100, UMC119-01, Pneumostem, OHB-607, INOmax, Furosemide Cohort 1, Inhaled Nitric Oxide, PNEUMOSTEM®, Curosurf, and others
• The Bronchopulmonary Dysplasia epidemiology based on gender analyzed that the severity‐specific data reveal the highest number of preterm infants have mild Bronchopulmonary Dysplasia
• The Bronchopulmonary Dysplasia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bronchopulmonary Dysplasia pipeline products will significantly revolutionize the Bronchopulmonary Dysplasia market dynamics.

Bronchopulmonary Dysplasia Overview
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that primarily affects premature infants, especially those born very prematurely or with low birth weight. It typically develops in infants who have received mechanical ventilation and oxygen therapy for acute respiratory distress syndrome (ARDS) or other conditions shortly after birth.

Get a Free sample for the Bronchopulmonary Dysplasia Market Report:
https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bronchopulmonary Dysplasia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Bronchopulmonary Dysplasia Epidemiology Segmentation:
The Bronchopulmonary Dysplasia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Incident cases of Bronchopulmonary Dysplasia in the 7MM
• Weight-specific cases of Bronchopulmonary Dysplasia in the 7MM
• Severity-specific cases of Bronchopulmonary Dysplasia in the 7MM

Download the report to understand which factors are driving Bronchopulmonary Dysplasia epidemiology trends @ Bronchopulmonary Dysplasia Epidemiology Forecast
https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bronchopulmonary Dysplasia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bronchopulmonary Dysplasia market or expected to get launched during the study period. The analysis covers Bronchopulmonary Dysplasia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Bronchopulmonary Dysplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Bronchopulmonary Dysplasia Therapies and Key Companies
• OHB-607: Chiesi Farmaceutici S.p.A.
• AVR-48: AyuVis Research
• AT-100: Airway Therapeutics, Inc
• UMC119-01: Meridigen Biotechnology
• Pneumostem: Medipost Co., Ltd.
• OHB-607: Oak Hill Bio Ltd.
• INOmax: Mallinckrodt
• Furosemide Cohort 1: The Emmes Company, LLC
• Inhaled Nitric Oxide: Mallinckrodt
• PNEUMOSTEM®: Medipost Co Ltd.
• Curosurf: Chiesi Farmaceutici S.p.A.

Discover more about therapies set to grab major Bronchopulmonary Dysplasia market share @ Bronchopulmonary Dysplasia Treatment Market
https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bronchopulmonary Dysplasia Market Drivers
Rising Preterm Birth Rates
Increasing incidence of premature births globally is expanding the at-risk neonatal population for bronchopulmonary dysplasia.

• Improved Neonatal Survival Rates: Advances in neonatal intensive care (NICU) management have improved survival of extremely low birth weight infants, inadvertently increasing BPD prevalence.
• High Unmet Clinical Need: Limited approved targeted therapies for BPD create strong demand for innovative treatments that prevent lung injury and support long-term pulmonary function.
• Advancements in Regenerative & Cell-Based Therapies: Growing research in mesenchymal stem cell (MSC) therapy, anti-inflammatory biologics, and growth factor modulation is strengthening the development pipeline.
• Increasing Healthcare Investment in Neonatal Care: Expansion of NICU infrastructure and government-backed maternal-child health programs are supporting earlier diagnosis and intervention.

Bronchopulmonary Dysplasia Market Barriers
• Limited Approved Pharmacologic Options: Current management relies largely on supportive care (oxygen therapy, ventilation strategies), with few disease-modifying drugs available.
• Complex Disease Pathophysiology: Multifactorial causes including inflammation, oxidative stress, and mechanical ventilation injury make targeted therapy development challenging.
• Small and Vulnerable Patient Population: Neonates represent a highly sensitive population, leading to strict safety requirements and ethical challenges in clinical trials.
• High Clinical Trial Costs & Recruitment Challenges: Conducting neonatal trials requires specialized centers, prolonged monitoring, and stringent regulatory oversight.

Scope of the Bronchopulmonary Dysplasia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Bronchopulmonary Dysplasia Companies: Chiesi Farmaceutici S.p.A., AyuVis Research, Airway Therapeutics, Inc, Meridigen Biotechnology, Medipost Co., Ltd., Oak Hill Bio Ltd., Mallinckrodt, The Emmes Company, LLC, Medipost Co Ltd, and others
• Key Bronchopulmonary Dysplasia Therapies: OHB-607, AVR-48, AT-100, UMC119-01, Pneumostem, OHB-607, INOmax, Furosemide Cohort 1, Inhaled Nitric Oxide, PNEUMOSTEM®, Curosurf, and others
• Bronchopulmonary Dysplasia Therapeutic Assessment: Bronchopulmonary Dysplasia current marketed and Bronchopulmonary Dysplasia emerging therapies
• Bronchopulmonary Dysplasia Market Dynamics: Bronchopulmonary Dysplasia market drivers and Bronchopulmonary Dysplasia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Bronchopulmonary Dysplasia Unmet Needs, KOL's views, Analyst's views, Bronchopulmonary Dysplasia Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.